Recently, our Commercial Operating Officer, Grant Boldt, PhD lent his thoughts to an industry article from Pharmaceutical Technology addressing the challenges posed by the limited bioavailability and stability in traditional drug development and delivery. He and other industry experts highlighted efforts to enhance stability and solubility, facilitate cellular entry, and ideally allow effective targeting of specific cells, tissues, and/or organs via alternative nanoscale technologies.
Learn more in the full Pharmaceutical Technology article by clicking here. Or reach out any time at info@cptx.bio to have a discussion.